A meta-analysis that included nine RCTs and 5,005 subjects conducted by Bongartz et al. [15] demonstrated a dose-dependent increased risk of malignancy in RA patients treated with TNF inhibitors, mainly infliximab and adalimumab. Here, TNF is linked to rheumatoid arthritis.